Lexicon Pharmaceuticals Inc (LXRX)
1.79
-0.10
(-5.04%)
USD |
NASDAQ |
May 10, 16:00
1.79
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Enterprise Value: 208.46M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 208.46M |
| May 08, 2024 | 180.14M |
| May 07, 2024 | 180.14M |
| May 06, 2024 | 194.91M |
| May 03, 2024 | 172.75M |
| May 02, 2024 | 162.90M |
| May 01, 2024 | 150.59M |
| April 30, 2024 | 123.50M |
| April 29, 2024 | 128.43M |
| April 26, 2024 | 133.35M |
| April 25, 2024 | 123.50M |
| April 24, 2024 | 138.28M |
| April 23, 2024 | 140.74M |
| April 22, 2024 | 165.36M |
| April 19, 2024 | 150.59M |
| April 18, 2024 | 145.66M |
| April 17, 2024 | 143.20M |
| April 16, 2024 | 161.67M |
| April 15, 2024 | 204.76M |
| April 12, 2024 | 229.39M |
| April 11, 2024 | 244.16M |
| April 10, 2024 | 241.70M |
| April 09, 2024 | 254.01M |
| April 08, 2024 | 258.93M |
| April 05, 2024 | 251.55M |
| Date | Value |
|---|---|
| April 04, 2024 | 251.55M |
| April 03, 2024 | 246.62M |
| April 02, 2024 | 288.48M |
| April 01, 2024 | 305.72M |
| March 31, 2024 | 335.27M |
| March 28, 2024 | 520.45M |
| March 27, 2024 | 468.74M |
| March 26, 2024 | 417.03M |
| March 25, 2024 | 451.50M |
| March 22, 2024 | 485.98M |
| March 21, 2024 | 522.91M |
| March 20, 2024 | 542.61M |
| March 19, 2024 | 530.30M |
| March 18, 2024 | 550.00M |
| March 15, 2024 | 569.70M |
| March 14, 2024 | 527.84M |
| March 13, 2024 | 540.15M |
| March 12, 2024 | 550.00M |
| March 11, 2024 | 621.41M |
| March 08, 2024 | 463.82M |
| March 07, 2024 | 458.89M |
| March 06, 2024 | 465.87M |
| March 05, 2024 | 480.56M |
| March 04, 2024 | 470.77M |
| March 01, 2024 | 536.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
32.22M
Minimum
Nov 02 2020
1.146B
Maximum
Feb 02 2021
385.07M
Average
339.63M
Median
Jan 23 2020
Enterprise Value Benchmarks
| Windtree Therapeutics Inc | -1.859M |
| AIM ImmunoTech Inc | 9.406M |
| Perspective Therapeutics Inc | 1.049B |
| Protalix BioTherapeutics Inc | 67.01M |
| Armata Pharmaceuticals Inc | 186.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -48.40M |
| Revenue (Quarterly) | 1.13M |
| Total Expenses (Quarterly) | 46.46M |
| EPS Diluted (Quarterly) | -0.20 |
| Gross Profit Margin (Quarterly) | 97.26% |
| Profit Margin (Quarterly) | -4.28K% |
| Earnings Yield | -46.37% |
| Normalized Earnings Yield | -46.37 |